Company Overview and News

An Inside Look Into My Portfolio Strategy And Holdings

14h seekingalpha
How did my portfolio perform over the Q1 2018, including my recent dispositions and stocks on my watchlist.

Netflix Inc. Proves Skeptics Wrong and the Stock Jumps | InvestorPlace

2018-04-17 investorplace
Netflix, Inc. (NASDAQ:NFLX), which had dropped $7 per share on April 16 over skepticism it could beat its earnings estimates, instead blew through them and rose almost 7% in premarket trading April 17.

Here Is How It All Could Go Wrong for Netflix, Inc. Stock

2018-04-12 investorplace
To be clear, I would not recommend a short of Netflix, Inc. (NASDAQ:NFLX) stock for a number of reasons. Netflix stock isn’t cheap, and some hardy souls are making that trade. Nearly 5% of the float of NFLX stock is sold short at the moment.

Top Gainers in the Consumer Sector Last Week

2018-04-10 marketrealist
Florida-based Lennar (LEN) released its fiscal 1Q18 results on April 4, 2018. Its revenue grew 27.6% YoY (year-over-year) to $2.9 billion from $2.3 billion, and its EPS (earnings per share) rose 42.4% YoY to $0.84 from $0.59. Revenue and EPS surpassed estimates by 12.1% and 9.1%, respectively. The stock rose 5.6% last week after the earnings release.

CBS-Viacom Deal Shouldn't Be Stopped Again By Egos - Bloomberg

2018-04-03 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

CBS plans all-stock bid for Viacom below current valuation, sources say

2018-04-02 themalaymailonline
The CBS television network logo is seen outside their offices on 6th avenue in New York. — Reuters picNEW YORK, April 3 ― CBS Corp plans to make an all-stock offer for Viacom Inc that values the US media company below its current market valuation, people familiar with the matter said yesterday, indicating that tough negotiations lie ahead.

Meredith (MDP) Continues to Restructure, Offloading MXM

2018-04-02 zacks
In keepingwith its strategy to focus on core operations, Meredith Corporation (MDP - Free Report) has decided to offload Meredith Xcelerated Marketing (“MXM”) to Accenture. Management believes that this digital and customer relationship marketing agency will better integrate with Accenture Interactive. MXM is a creative agency, which develops and delivers custom content and customer relationship marketing programs for many of the world's leading brands.

Netflix Reportedly Casts Jennifer Aniston in Murder Mystery

2018-04-02 zacks
Netflix (NFLX - Free Report) has been one of the top-performing stocks to-date in 2018 driven by its robust and ever expanding content portfolio. The company’s strategy of producing quality original content and strong programming slate will continue to help it in attracting and retaining subscriber base. Netflix’s massive spending on content can primarily be attributed to high production values. Notably, the solid budget also attracts well-known Hollywood stars, which definitely make the shows more attractive.

Discovery (DISCA) Down 16.7% Since Earnings Report: Can It Rebound?

2018-03-29 zacks
It has been about a month since the last earnings report for Discovery Communications, Inc. (DISCA - Free Report) . Shares have lost about 16.7% in that time frame.

New Strong Buy Stocks for March 28th

2018-03-28 zacks
Applied Materials, Inc. (AMAT - Free Report) : This company that provides manufacturing equipment, services, and software has seen the Zacks Consensus Estimate for its current year earnings increasing 8.1% over the last 60 days.

Consumer Confidence Remains Strong: 4 Top-Ranked Picks

2018-03-28 zacks
On Mar 27, the Conference Board reported U.S. consumer confidence data for the month of March. In February, consumer confidence index was at its 18-years high. Although the data shows a moderate dip from the previous month, primarily due to stock market fluctuations, it still remains at a strong level. Expected improvement in income, jobs and after-tax pay of U.S. consumers are most likely to offset worries about rising interest rates and stock market volatility.

Turner Sports Service to Let Fans Buy Portions of NBA Games - Bloomberg

2018-03-27 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Brexit Is a Year Away. Here’s What’s Happening in the U.K. - Bloomberg

2018-03-27 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

New Strong Buy Stocks for March 26th

2018-03-26 zacks
Applied Materials, Inc. (AMAT - Free Report) : This provider of manufacturing equipment, services, and software has seen the Zacks Consensus Estimate for its current year earnings increasing 8.1% over the last 60 days.

Meredith Reshapes Media Portfolio For Time Inc's Integration

2018-03-23 zacks
Meredith Corporation (MDP - Free Report) unveiled strategic plans to smoothly integrate its recent buyout of Time Inc. This strategy mainly comprises reviewing of media assets’ portfolio and divestiture of non-core brands; augment advertising as well as circulation feat of the Time Inc. properties; increasing revenue and profits of Time Inc. digital assets; and generate cost synergies in a band of $400-$500 million annually in the first two years of operations.

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...